Asked by: Jonathan Edwards (Independent - Carmarthen East and Dinefwr)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with the Secretary of State for Exiting the European Union on the UK remaining in the EU Medicines Agency and complying with EU regulations for medicines after the UK leaves the EU.
Answered by Jackie Doyle-Price
The United Kingdom is fully committed to continuing the close working relationship with our European partners, and as part of the negotiations the Government will discuss with the European Union and Member States how best to continue cooperation in the field of medicines regulation (including with the European Medicines Agency).
Our aim is to ensure that patients in the UK and across the EU continue to be able to access the best and most innovative medicines, and be assured that their safety is protected through the strongest regulatory framework and sharing of data. Whatever the outcome of Brexit negotiations, we are clear that our regulatory system that protects the best interests of patients and supports the UK life science industry to go from strength to strength.
We are in regular contact with the pharmaceutical industry through the Ministerial and industry co-chaired UK-European Union Life Sciences Steering Group. Outside of this group we have consistent contact with industry and research charities.
As a member of the Cabinet, the Secretary of State has regular discussions with all Cabinet colleagues, including on Brexit.
Asked by: Jonathan Edwards (Independent - Carmarthen East and Dinefwr)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the benefits to the UK of complying with EU regulation for medicines after the UK has left the EU.
Answered by Jackie Doyle-Price
The United Kingdom is fully committed to continuing the close working relationship with our European partners, and as part of the negotiations the Government will discuss with the European Union and Member States how best to continue cooperation in the field of medicines regulation (including with the European Medicines Agency).
Our aim is to ensure that patients in the UK and across the EU continue to be able to access the best and most innovative medicines, and be assured that their safety is protected through the strongest regulatory framework and sharing of data. Whatever the outcome of Brexit negotiations, we are clear that our regulatory system that protects the best interests of patients and supports the UK life science industry to go from strength to strength.
We are in regular contact with the pharmaceutical industry through the Ministerial and industry co-chaired UK-European Union Life Sciences Steering Group. Outside of this group we have consistent contact with industry and research charities.
As a member of the Cabinet, the Secretary of State has regular discussions with all Cabinet colleagues, including on Brexit.
Asked by: Jonathan Edwards (Independent - Carmarthen East and Dinefwr)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, how many times Corneal Cross-Linking (CXL) treatment has been undertaken by the NHS in each of the last five financial years.
Answered by Steve Brine
This information is not held centrally.
Asked by: Jonathan Edwards (Independent - Carmarthen East and Dinefwr)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what recent estimate his Department has made of the number of armed forces veterans in inpatient and outpatient mental healthcare in England.
Answered by Jackie Doyle-Price
The table below shows the number of ex-British Armed Forces veterans in contact with mental health services plus the number of ex-British Armed Forces veterans in a mental health hospital at the end of July 2017 in England only. The figure in row one includes those accessing service as outpatients and in the community.
Ex-British Armed Forces veterans in contact with mental health services at the end of July 2017 | 4,644 |
Ex-British Armed Forces veterans in mental health hospitals at the end of July 2017 | 57 |
Source: Mental Health Services Dataset (MHSDS)
The MHSDS has identified ex-British Armed Forces veteran’s status from 2016/17.
Asked by: Jonathan Edwards (Independent - Carmarthen East and Dinefwr)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what representations he has received from local authorities in England on prohibiting smoking on beaches; and if he will make a statement.
Answered by Jane Ellison
The Department has received no representations from local authorities on prohibiting smoking on beaches. The Government has no current plans to extend smokefree legislation to open public areas.
Asked by: Jonathan Edwards (Independent - Carmarthen East and Dinefwr)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what discussions he is having with (a) his counterparts in the devolved administrations and (b) representatives of GPs on reducing the number of anti-depressants prescribed to young people.
Answered by Alistair Burt
There have not been any discussions between my Rt. hon. Friend the Secretary of State for Health and his counterparts in the devolved administrations or with representatives of general practitioners to specifically discuss reducing the number of anti-depressants prescribed to young people.
Asked by: Jonathan Edwards (Independent - Carmarthen East and Dinefwr)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what pharmaceutical companies supplied the Government's stockpile of Tamiflu.
Answered by Jane Ellison
Roche is the only supplier of the Government's stockpile of Tamiflu. There are currently no other suppliers of Tamiflu.